Contemporary Problems of Cardiovascular Disorders at Diabetes Mellitus
Issue:
Volume 1, Issue 1, December 2016
Pages:
1-7
Received:
17 October 2016
Accepted:
16 November 2016
Published:
17 December 2016
DOI:
10.11648/j.ijde.20160101.11
Downloads:
Views:
Abstract: At the present time, the number of patients with comorbid cardiometabolic dysfunctions, which cause more early onsets of cardiovascular diseases (CVD) and their quick progressions, has increased. Results of studies permit to suggest that such high comorbidity of cardiovascular diseases and diabetes mellitus (DM) are caused by commonness of pathogenic mechanisms. Special attention should be given to predictors of cardiac dysfunctions occurrence in cases of diabetes mellitus, which will allow to improve prognosis for a patient and to decrease risk of death. In the article, there are outlined contemporary problems of important cardiovascular dysfunctions in cases of progression of diabetes mellitus; that will allow to draw attention of doctors to the most complicated problems of comorbid cardiometabolic disorders.
Abstract: At the present time, the number of patients with comorbid cardiometabolic dysfunctions, which cause more early onsets of cardiovascular diseases (CVD) and their quick progressions, has increased. Results of studies permit to suggest that such high comorbidity of cardiovascular diseases and diabetes mellitus (DM) are caused by commonness of pathogen...
Show More
Evaluation the Effect of Glyburide and/or Metformin on Testosterone Levels in Men Patients with Type 2 Diabetes Mellitus
Hayder M. Al-kuraishy,
Ali I. Al-Gareeb,
Salah A. Al-Windy
Issue:
Volume 1, Issue 1, December 2016
Pages:
8-12
Received:
4 November 2016
Accepted:
2 December 2016
Published:
27 December 2016
DOI:
10.11648/j.ijde.20160101.12
Downloads:
Views:
Abstract: Low testosterone serum levels have been linked with pathogenesis of type 2DM. Type 2DM pharmacotherapy may also affect the testosterone levels since; metformin decreases testosterone levels, whereas glyburide might increase the testosterone levels. Sixty-one men patients with type 2DM were selected: 22 of patients were treated with metformin, 20 of patients were treated with glyburide and 19 patients were treated with glyburide plus metformin the duration of disease was 3-6 years, compared with 20 normal healthy volunteers. Total testosterone, free testosterone and other biochemical measures as well as anthropometric variables were evaluated in each treated group. In glyburide or metformin treated patients, there were significant reduction in testosterone serum levels regarding the total and free testosterone p<0.01whereas patients that were treated with combined glyburide plus metformin there was an insignificant reduction in both total and free testosterone p>0.5. Conclusion: Combined therapy of metformin plus glyburide in type 2DM lead to a significant increment in the testosterone levels, which may play an important role in the amelioration of metabolic complications that are induced by type 2 DM.
Abstract: Low testosterone serum levels have been linked with pathogenesis of type 2DM. Type 2DM pharmacotherapy may also affect the testosterone levels since; metformin decreases testosterone levels, whereas glyburide might increase the testosterone levels. Sixty-one men patients with type 2DM were selected: 22 of patients were treated with metformin, 20 of...
Show More
Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus
Alok Raghav,
Jamal Ahmad,
Maaz Ozair,
Saba Noor,
Zeeshan Ahmad Khan,
Brijesh Kumar Mishra
Issue:
Volume 1, Issue 1, December 2016
Pages:
13-15
Received:
2 November 2016
Accepted:
29 December 2016
Published:
23 January 2017
DOI:
10.11648/j.ijde.20160101.13
Downloads:
Views:
Abstract: Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.
Abstract: Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones an...
Show More
